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Using two different and complementary approaches (flow cytometry and immunohistochemistry) on two independent
cohorts of ovarian cancer patients, we found that accumulation of plasmacytoid dendritic cells (pDC) in tumors is
associated with early relapse. This deleterious effect of tumor-associated pDC was evident when they are present in
cancer epithelium but not in lymphoid aggregates.
Plasmacytoid dendritic cells (pDC) are
one of the two main subsets of DC in
human blood. They play a major role
in anti-viral and autoimmune responses
through their unique capacity to produce
massive amounts of IFNa in response to
both viral and self nucleic acids, respec-
tively, following TLR7 and TLR9 engage-
ment.
1 However, their role in antitumor
immunity has not been clarified yet.
Emerging evidence indicates that tumor
infiltration by pDC may have clinical
importance, as underlined by their identi-
fication in melanoma, head and neck,
lung, ovarian and breast cancers.
1
Ovarian cancer (OC) is the most
frequent and aggressive gynecologic can-
cer. This is due, at least in part, to its
diagnosis at advanced stages (III/IV) in the
majority of patients with peritoneal carci-
nosis and malignant ascites. In a recent
report,
2 we investigated the clinical sig-
nificance of the presence of pDC in tumor
mass and malignant ascites by conducting
a systematic comparison of tumor-asso-
ciated (TA) and ascites pDC. We observed
an accumulation of pDC in most of
malignant ascites and their presence at
high frequency (highest tertile) in 36% of
tumors whereas they were profoundly
depleted in blood. Importantly, only
accumulation of pDC in tumors was an
independent prognostic factor associated
with early relapse while their presence in
malignant ascites was not deleterious.
These initial results obtained on 33
patients in whom pDC were identified by
flow-cytometry as CD4
+BDCA2
+CD123
+
cells
2 were confirmed on a larger series (n =
97 patients) treated for OC in Centre
Leon Berard between 1997 and 2009 by
immunohistochemistry (IHC). Thus,
TApDC were identified as BDCA2
+ cells
(clone 104C12, Dendritics) on formalin-
fixed, paraffin-embedded tissues using
tissue microarray allowing the analysis of
impact of the presence of pDC in both
cancer epithelium and lymphoid aggre-
gates present in cancer stroma. BDCA2
+
cells frequency was scored using a semi-
quantitative method as 0 (no cells)
(Fig.1A), + (# 5 cells) (Fig.1B) and ++
(. 5 cells) (Fig.1C). BDCA2
+ TApDC
were present in only 18/97 tumors (18%)
with a majority (73%) of score +. The
median follow-up of the cohort was
34.1 mo. In univariate analysis, the pre-
sence of TApDC within cancer epithelium
was associated with early relapse, as median
progression-free survival (PFS) was esti-
mated to 14.6 mo, compared with 26.2 mo
in the absence of TApDC (p = 0.01,
Fig.1D). Similarly, median overall survival
was shorter in the presence of TApDC,
although not statistically significant
(34.3 mo compared with 67.5 mo, p =
0.09; Fig.1E). In multivariate analysis, in
addition to clinical prognostic factors
(advanced stage, debulking surgery and
residual tumor), the presence of TApDC
remains an independent prognostic factor
associated with shorter PFS (HR = 2.19,
95%IC = 1.1–4.07, p = 0.02).
Interestingly, the presence of TApDC
into lymphoid aggregates had no impact on
clinical outcome, suggesting a direct inter-
action between TApDC and tumor cells
favoring tumor progression. Thus, using
two different and complementary methods
(flow-cytometry and IHC) on two inde-
pendent cohorts, we observed a deleterious
impact of the presence of TApDC within
tumors on OC patient’s outcome. These
data corroborate our findings in breast
cancer
3 and others in melanoma
4 showing
that TApDC accumulation correlates with
poor prognosis. Collectively, these results
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immune tolerance and tumor progression.
In our initial report in OC,
2 we showed
that, unlike ascites pDC, TApDC (1)
expressed a semi-mature phenotype as
evidenced by high levels of CD40 and
CD86 and (2) were strongly affected for
their IFNa production in response to
CpG-A (TLR9 ligand) known to induce
huge amounts of Type I IFNs. The
alteration of IFNa production by pDC
in response to TLR ligands has been
previously described in chronic viral infec-
tions such as HIV and HCV contributing
to the failure of an efficient immune
response.
5 In the context of cancer,
previous works have also reported this
alteration in breast,
3 lung and head and
neck cancers
1 and chronic myeloid leuke-
mia (CML).
6 Type I IFNs promote
immunosurveillance through the activa-
tion of innate immune cells (reviewed in
ref. 7) and inhibition of regulatory T
cells.
8 The critical role of type I IFNs
in anti-tumor immunosurveillance is also
well demonstrated in IFNa receptor
1-deficient mice where tumor growth is
exacerbated.
7 IFNa has also direct
antitumor activities in OC in vitro and
in vivo either in nude mice when asso-
ciated to paclitaxel or in patients with
minimal residual tumor
9 by inhibiting OC
cell proliferation, tumor growth and
angiogenesis. Thus, the inhibition of
IFNa production by TApDC in tumor
microenvironment might confer a selective
advantage for tumor cells allowing their
progression.
In addition to altered immunosurveil-
lance function, a direct contribution of
pDC to tumor progression has been
reported in multiple myeloma (MM) and
Figure1. The presence of plasmacytoid dendritic cells (pDC) in ovarian cancer (OC) epithelium is associated with early relapse. (A–C) IHC analysis
on paraffin-embedded ovarian tumor sections was performed using anti-BDCA2 (brown). Representative pictures of BDCA2
+ pDC infiltration of OC
epithelium scored as 0 (A), + (B) and ++ (C) are shown. Original magnification: x40. (D) Progression-free survival (PFS) according to the presence (+/++)
or absence (0) of BDCA2
+ pDC in OC epithelium (n = 97 OC patients). (E) Overall survival (OS) according to presence (+/++) or absence (0) of BDCA2
+ pDC
in OC epithelium (n = 97 OC patients). PFS and OS were calculated using Kaplan–Meier method.
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1 Indeed, pDC in the bone
marrow microenvironment promote MM
cell growth, survival and drug resistance
and pDC isolated from ovarian malignant
ascites induce tumor angiogenesis in vivo
in immunodeficient mice.
1 In this context,
it would be interesting to evaluate the
impact of TApDC on tumor cell cycling
and angiogenesis in situ in ovarian tumors.
Currently, we assist to a renaissance of
IFN therapy for the treatment of myeloid
malignancies. Preliminary results of a
Phase III clinical trial in CML showed that
a pegylated form of IFNa2a (pegIFNa2)
in association with imatinib doubled
molecular response (30%) in comparison
to imatinib alone (14%, p = 0.001).
10
By analogy to CML, the association of
pegIFNa2a to chemotherapy could
improve outcome in OC. Thus, restoring
pDC capacity to produce Type I IFNs
represents an attractive therapeutic strategy
in cancer. In this context, the treatment
of skin cancers with imiquimod (TLR7
ligand) resulted in IFNa production by
TApDC that correlates to local immune
reaction and destruction of tumor lesions.
1
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